Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aptevo Therapeutics Inc (APVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,045
  • Shares Outstanding, K 22,808
  • Annual Sales, $ 14,660 K
  • Annual Income, $ 6,970 K
  • 60-Month Beta 3.00
  • Price/Sales 0.84
  • Price/Cash Flow N/A
  • Price/Book 0.63
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.77
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/09/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.45
  • Number of Estimates 1
  • High Estimate -0.45
  • Low Estimate -0.45
  • Prior Year -0.63
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.79 +5.70%
on 03/07/19
1.73 -51.73%
on 02/21/19
-0.82 (-49.70%)
since 02/20/19
3-Month
0.79 +5.70%
on 03/07/19
2.00 -58.25%
on 02/05/19
-0.56 (-40.36%)
since 12/20/18
52-Week
0.79 +5.70%
on 03/07/19
6.35 -86.85%
on 05/17/18
-2.02 (-70.80%)
since 03/20/18

Most Recent Stories

More News
Aptevo Therapeutics Begins Phase 1 Clinical Trial of APVO210 a Novel Bispecific Antibody for the Treatment of Autoimmune and Inflammatory Diseases

Unique Mechanism of Action Suppresses Inflammation and Immune Activation Without Promoting Pro-Inflammatory Lymphocyte Stimulation

APVO : 0.83 (-1.21%)
Aptevo Therapeutics Reports 2018 Financial Results and Provides Business Update

Achieves Record Annual IXINITY Net Revenue of $23.1 Million Representing 111% Increase Over 2017

APVO : 0.83 (-1.21%)
Aptevo Therapeutics Inc. (APVO) Moves to Buy: Rationale Behind the Upgrade

Aptevo Therapeutics Inc. (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

APVO : 0.83 (-1.21%)
Aptevo Announces Pricing of $22 Million Offering of Common Stock and Warrants

Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced the pricing of (i) for a combined public offering...

APVO : 0.83 (-1.21%)
Aptevo Announces Proposed Public Offering of Common Stock and Warrants

Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced that it intends to offer and sell, subject...

APVO : 0.83 (-1.21%)
Aptevo Therapeutics Highlights Key 2019 Priorities

ADAPTIR(TM) Bispecific Antibody Candidates Poised to Progress in Clinical Development

APVO : 0.83 (-1.21%)
Aptevo Therapeutics Collects $3.3 Million In Escrow Funds From Saol Therapeutics

Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that it has collected $3.3 million in escrow funds from...

APVO : 0.83 (-1.21%)
Aptevo Therapeutics Announces Up To $35 Million Common Stock Purchase Agreement With Lincoln Park Capital

Provides Opportunistic Capital of up to $35 Million to Aptevo During the 36-month Term of the Agreement

APVO : 0.83 (-1.21%)
Aptevo Therapeutics Doses First Patient in Phase 1/1b Clinical Trial of Lead Next-Generation Bispecific Antibody APVO436

Preclinical Data for APVO436 Show Potential Best-in-Class Attributes with Potent T-Cell Directed Tumor Killing and Reduced Cytokine Production Compared to a Competitor Construct

APVO : 0.83 (-1.21%)
United Parcel Service, Endurance International Group, Idera Pharmaceuticals, Aptevo Therapeutics, and Electro Scientific Industries -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mercer International Inc. (NASDAQ:MERC),...

SCND : 4.9500 (+3.12%)
ESIO : 29.99 (-0.03%)
EIGI : 6.61 (+0.46%)
APVO : 0.83 (-1.21%)
IDRA : 3.15 (+3.62%)
UPS : 107.92 (-2.20%)
MERC : 13.80 (+0.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade APVO with:

Business Summary

Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics...

See More

Key Turning Points

2nd Resistance Point 0.98
1st Resistance Point 0.91
Last Price 0.83
1st Support Level 0.80
2nd Support Level 0.76

See More

52-Week High 6.35
Fibonacci 61.8% 4.23
Fibonacci 50% 3.57
Fibonacci 38.2% 2.91
Last Price 0.83
52-Week Low 0.79

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar